Agreement Between Mega-Trials and Smaller Trials

Author:

Kastrati Lum1234,Raeisi-Dehkordi Hamidreza5,Llanaj Erand678,Quezada-Pinedo Hugo G.9,Khatami Farnaz2310,Ahanchi Noushin Sadat2311,Llane Adea6,Meçani Renald612,Muka Taulant16,Ioannidis John P. A.113141516

Affiliation:

1. Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California

2. Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland

3. Graduate School for Health Sciences, University of Bern, Bern, Switzerland

4. Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, University of Bern, Switzerland

5. Department of Global Public Health and Bioethics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands

6. Epistudia, Bern, Switzerland

7. Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbrücke, Nuthetal, Germany

8. German Centre for Diabetes Research (DZD), München-Neuherberg, Germany

9. Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina

10. Community Medicine Department, Tehran University of Medical Sciences, Tehran, Iran

11. Department of Internal Medicine, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland

12. Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

13. Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, California

14. Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California

15. Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, California

16. Department of Statistics, Stanford University School of Humanities and Sciences, Stanford, California

Abstract

ImportanceMega-trials can provide large-scale evidence on important questions.ObjectiveTo explore how the results of mega-trials compare with the meta-analysis results of trials with smaller sample sizes.Data SourcesClinicalTrials.gov was searched for mega-trials until January 2023. PubMed was searched until June 2023 for meta-analyses incorporating the results of the eligible mega-trials.Study SelectionMega-trials were eligible if they were noncluster nonvaccine randomized clinical trials, had a sample size over 10 000, and had a peer-reviewed meta-analysis publication presenting results for the primary outcome of the mega-trials and/or all-cause mortality.Data Extraction and SynthesisFor each selected meta-analysis, we extracted results of smaller trials and mega-trials included in the summary effect estimate and combined them separately using random effects. These estimates were used to calculate the ratio of odds ratios (ROR) between mega-trials and smaller trials in each meta-analysis. Next, the RORs were combined using random effects. Risk of bias was extracted for each trial included in our analyses (or when not available, assessed only for mega-trials). Data analysis was conducted from January to June 2024.Main Outcomes and MeasuresThe main outcomes were the summary ROR for the primary outcome and all-cause mortality between mega-trials and smaller trials. Sensitivity analyses were performed with respect to the year of publication, masking, weight, type of intervention, and specialty.ResultsOf 120 mega-trials identified, 41 showed a significant result for the primary outcome and 22 showed a significant result for all-cause mortality. In 35 comparisons of primary outcomes (including 85 point estimates from 69 unique mega-trials and 272 point estimates from smaller trials) and 26 comparisons of all-cause mortality (including 70 point estimates from 65 unique mega-trials and 267 point estimates from smaller trials), no difference existed between the outcomes of the mega-trials and smaller trials for primary outcome (ROR, 1.00; 95% CI, 0.97-1.04) nor for all-cause mortality (ROR, 1.00; 95% CI, 0.97-1.04). For the primary outcomes, smaller trials published before the mega-trials had more favorable results than the mega-trials (ROR, 1.05; 95% CI, 1.01-1.10) and subsequent smaller trials published after the mega-trials (ROR, 1.10; 95% CI, 1.04-1.18).Conclusions and RelevanceIn this meta-research analysis, meta-analyses of smaller studies showed overall comparable results with mega-trials, but smaller trials published before the mega-trials gave more favorable results than mega-trials. These findings suggest that mega-trials need to be performed more often given the relative low number of mega-trials found, their low significant rates, and the fact that smaller trials published prior to mega-trial report more beneficial results than mega-trials and subsequent smaller trials.

Publisher

American Medical Association (AMA)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3